Print
Email
Print Edition StoriesMonday, March 8, 2010
Rcadia grabs European OK for cardiac CT analyzer
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Robotic surgery gains traction
Funding drugs for rare diseases
Rcadia Medical Imaging Ltd. of Newton says it has won approval in Europe for its automated analysis system for detecting coronary artery disease from a coronary CT scan.
According to company officials, Rcadia received a CE Mark for its COR Analyzer System, and that gives the company the go-ahead to market the system in the European Union and any other countries that accept the CE Mark registration. Rcadia was founded in Israel and maintains research operations there.
In December of 2008, Cambridge’s BioVentures Investors and 20/20 HealthCare Partners LLC of Boston participated in Rcadia’s $3.3 million investment round. That funding helped the commercial launch of the COR Analyzer and the establishment of the Newton office as the company’s U.S. headquarters, officials said at the time.
Rcadia president and CEO Shai Levanon said that the COR Analyzer system’s ability to get results in real time has “great potential in emergency department triage” by allowing them to rule out coronary artery disease in chest pain patients. The COR Analyzer has already been approved for sale in the United States.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
